Rani Therapeutics (NASDAQ:RANI) announces earnings results, beats expectations by $0.01 EPS. August 13, 2026 Key points. * Rani Therapeutics beat quarterly expectations: The company reported an adjusted loss of $0.04 per share versus the expected $0.05 loss, while revenue of $1.71 million exceeded estimates of $0.93 million. * The stock remains under pressure: Shares traded around $0.80, within a 12-month range of $0.44 to $3.87, with a market capitalization of approximately $98.8 million. * Analyst sentiment is cautiously positive: Four analysts rate the stock Buy and one rates it Sell, producing a "Moderate Buy" consensus and an average price target of $8.75; CEO Talat Imran also recently purchased 35,000 shares. * MarketBeat previews top five stocks to own in September. Rani Therapeutics (NASDAQ:RANI - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01, FiscalAI reports. The business had revenue of $1.71 million during the quarter, compared to analysts' expectations of $0.93 million. Rani Therapeutics price performance. NASDAQ RANI traded down $0.00 during mid-day trading on Thursday, hitting $0.80. The stock had a trading volume of 358,630 shares, compared to its average volume of 1,007,880. The firm's 50 day moving average is $0.77 and its 200 day moving average is $0.98. The stock has a market capitalization of $98.84 million, a price-to-earnings ratio of -1.95 and a beta of 0.78. Rani Therapeutics has a twelve month low of $0.44 and a twelve month high of $3.87. Insider transactions at Rani Therapeutics. In other Rani Therapeutics news, CEO Talat Imran bought 35,000 shares of Rani Therapeutics stock in a transaction dated Friday, July 17th. The stock was acquired at an average cost of $0.72 per share, for a total transaction of $25,200.00. Following the completion of the transaction, the chief executive officer directly owned 469,736 shares of the company's stock, valued at approximately $338,209.92. This represents a 8.05% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 26.73% of the stock is currently owned by company insiders. Institutional inflows and outflows. Several institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new stake in Rani Therapeutics in the 4th quarter valued at $465,000. Siren L.L.C. acquired a new position in shares of Rani Therapeutics during the 4th quarter valued at about $2,700,000. State Street Corp grew its holdings in shares of Rani Therapeutics by 519.8% in the fourth quarter. State Street Corp now owns 387,042 shares of the company's stock valued at $523,000 after purchasing an additional 324,600 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Rani Therapeutics during the fourth quarter worth about $386,000. Finally, Geode Capital Management LLC raised its stake in Rani Therapeutics by 190.0% during the fourth quarter. Geode Capital Management LLC now owns 860,941 shares of the company's stock worth $1,163,000 after purchasing an additional 564,031 shares during the period. 30.19% of the stock is currently owned by institutional investors and hedge funds. Wall Street analysts forecast growth. RANI has been the subject of several analyst reports. Wall Street Zen upgraded shares of Rani Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, May 17th. Weiss Ratings cut shares of Rani Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $5.00 target price on shares of Rani Therapeutics in a research note on Wednesday, May 20th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Rani Therapeutics has an average rating of "Moderate Buy" and an average target price of $8.75. Discover more AI infrastructure stocks Insider trades screener Stock profit calculator About Rani Therapeutics. Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company's proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones. Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Rani Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list. While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Rani Therapeutics has granted a stock option to purchase 2 million shares of Class A common stock to Nicholas Maestas, its new chief financial officer. The option, granted on 17 July 2026, has an exercise price of $0.6973 per share, matching the closing price on the grant date. The option has a ten-year term and vests over four years. Twenty-five per cent of the shares vest after one year, with the remainder vesting monthly over the following 36 months, subject to continued employment. The San Jose-based clinical-stage biotherapeutics company focuses on oral delivery of biologics and drugs through its RaniPill capsule technology, which aims to replace subcutaneous injections or intravenous infusions with oral dosing.